Inogen, Inc. (NASDAQ:INGN - Get Free Report) shares passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $9.46 and traded as high as $10.33. Inogen shares last traded at $10.33, with a volume of 212,332 shares trading hands.
Analysts Set New Price Targets
A number of research firms have recently issued reports on INGN. StockNews.com cut shares of Inogen from a "buy" rating to a "hold" rating in a research note on Friday, December 20th. Needham & Company LLC reissued a "hold" rating on shares of Inogen in a report on Tuesday.
Get Our Latest Report on Inogen
Inogen Stock Performance
The stock has a market capitalization of $252.95 million, a price-to-earnings ratio of -4.72 and a beta of 1.02. The business has a fifty day simple moving average of $9.46 and a 200 day simple moving average of $9.88.
Institutional Trading of Inogen
A number of institutional investors have recently bought and sold shares of the business. Meeder Asset Management Inc. bought a new position in shares of Inogen in the second quarter worth $30,000. Quarry LP acquired a new stake in Inogen during the third quarter worth about $59,000. Verition Fund Management LLC bought a new position in Inogen in the 3rd quarter valued at about $106,000. Virtu Financial LLC acquired a new position in shares of Inogen in the 3rd quarter valued at approximately $111,000. Finally, Paloma Partners Management Co bought a new stake in shares of Inogen during the 3rd quarter worth approximately $126,000. Institutional investors own 89.94% of the company's stock.
About Inogen
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
